Regenxbio Inc (RGNX)

$8.06 -2.66 (-24.86%)
Market Cap 707.66M
Revenue (ttm) 170.44M
Net Income (ttm) -193.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -113.75%
Debt to Equity Ratio 0.00
Volume 5,441,256
Avg Vol 2,059,256
Day's Range N/A - N/A
Shares Out 66.01M
Stochastic %K 30%
Beta 0.94
Analysts Strong Sell
Price Target $26.25

Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 552 8181
Address:
9804 Medical Center Drive, Rockville, United States
IGOTACALL
IGOTACALL Aug. 24 at 7:50 PM
$RGNX dippy yippy
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 24 at 7:18 PM
RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ‘Disappointing’ FDA Hold On Gene Therapy $RGNX $XBI $VTI https://stocktwits.com/news/equity/markets/rgnx-stock-on-track-for-worst-day-in-over-three-months-bof-a-says-buy-despite-disappointing-fda-hold-on-gene-therapy/cZYKq3aRJFj
0 · Reply
IGOTACALL
IGOTACALL Aug. 24 at 6:47 PM
$RGNX tomorrow 6 ready for the dip before the bell
0 · Reply
maphere
maphere Aug. 24 at 6:39 PM
$RGNX Could see a late breaking abstract end of Sept. at the WMS conference. Abstract submissions are due by this week and Regenxbio has more data on 202 to share. https://www.wms2026.com/page/late-breaking-abstracts
1 · Reply
rando321456
rando321456 Aug. 24 at 6:09 PM
$RGNX Silver lining to this is that there's probably been nothing too bad around the confirmatory trial for 202 as the FDA definitely would have slapped a hold on it if there was anything. *knocks on wood* It'll be interesting to see if there's any buying into any of their stuff now, there's a decent chance they get blackballed until any approvals actually happen.
2 · Reply
hhsll
hhsll Aug. 24 at 6:06 PM
$RGNX back over $10 within a week
0 · Reply
BioRich
BioRich Aug. 24 at 5:51 PM
$RGNX $CAPR $MLTX did you get your cheapies?
0 · Reply
severeblast
severeblast Aug. 24 at 5:35 PM
$RGNX Losers trend..
0 · Reply
Ml55totoag
Ml55totoag Aug. 24 at 5:34 PM
$RGNX
0 · Reply
InfoLib
InfoLib Aug. 24 at 5:34 PM
$RGNX FDA clinical hold changes the setup immediately. This is now a regulatory path and safety interpretation trade. The next useful information is scope of the hold, remediation path and whether timelines elsewhere in the program move with it.
1 · Reply
Latest News on RGNX
RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold

Aug 24, 2026, 2:18 PM EDT - 3 hours ago

RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold

BofA says Regenxbio’s MPS setback ‘disappointing,’ larger catalysts intact

2026-08-24T15:30:08.000Z - 6 hours ago

BofA says Regenxbio’s MPS setback ‘disappointing,’ larger catalysts intact

Morning Movers: Regenxbio sinks following clinical hold on RGX-121

2026-08-24T13:00:24.000Z - 9 hours ago

Morning Movers: Regenxbio sinks following clinical hold on RGX-121

BABA ERAS GGR GOOS NSSC PDD XPEV

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

Aug 24, 2026, 8:39 AM EDT - 9 hours ago

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

Regenxbio to resume trading at 7:25 am ET

2026-08-24T11:25:11.000Z - 10 hours ago

Regenxbio to resume trading at 7:25 am ET

FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome

Aug 24, 2026, 7:25 AM EDT - 10 hours ago

FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome

Regenxbio reports FDA placed clinical hold on RGX-121

2026-08-24T11:20:06.000Z - 10 hours ago

Regenxbio reports FDA placed clinical hold on RGX-121

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

Aug 24, 2026, 7:05 AM EDT - 11 hours ago

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

Regenxbio price target lowered to $23 from $26 at H.C. Wainwright

2026-08-10T10:21:13.000Z - 14 days ago

Regenxbio price target lowered to $23 from $26 at H.C. Wainwright

Regenxbio price target raised to $18 from $16 at Morgan Stanley

2026-08-07T13:51:02.000Z - 17 days ago

Regenxbio price target raised to $18 from $16 at Morgan Stanley

Regenxbio downgraded to Equal Weight from Overweight at Barclays

2026-08-07T09:15:51.000Z - 17 days ago

Regenxbio downgraded to Equal Weight from Overweight at Barclays

REGENXBIO Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 18 days ago

REGENXBIO Earnings Call Transcript: Q2 2026

REGENXBIO Earnings release: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 18 days ago

REGENXBIO Earnings release: Q2 2026

REGENXBIO Quarterly report: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 18 days ago

REGENXBIO Quarterly report: Q2 2026

Regenxbio reports Q2 EPS 43c vs. ($1.38) last year

2026-08-06T11:33:11.000Z - 18 days ago

Regenxbio reports Q2 EPS 43c vs. ($1.38) last year

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

Aug 6, 2026, 7:05 AM EDT - 18 days ago

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

Aug 3, 2026, 7:05 AM EDT - 21 days ago

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

Regenxbio presents long-term data for surabgene lomparvovec

2026-07-19T15:45:15.000Z - 5 weeks ago

Regenxbio presents long-term data for surabgene lomparvovec

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

Jul 18, 2026, 2:55 PM EDT - 5 weeks ago

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

Regenxbio 10M share Spot Secondary priced at $9.00

2026-07-17T11:05:39.000Z - 5 weeks ago

Regenxbio 10M share Spot Secondary priced at $9.00

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

Jul 17, 2026, 7:00 AM EDT - 5 weeks ago

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

Regenxbio announces $100M common stock offering

2026-07-16T20:30:11.000Z - 5 weeks ago

Regenxbio announces $100M common stock offering

REGENXBIO Announces Proposed Public Offering of Common Stock

Jul 16, 2026, 4:26 PM EDT - 5 weeks ago

REGENXBIO Announces Proposed Public Offering of Common Stock

Regenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial

2026-06-29T11:20:21.000Z - 2 months ago

Regenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial

ABBV

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

Jun 29, 2026, 7:05 AM EDT - 2 months ago

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

Regenxbio completes dosing in confirmatory study of RGX-202

2026-06-24T11:10:54.000Z - 2 months ago

Regenxbio completes dosing in confirmatory study of RGX-202

REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026

Jun 24, 2026, 7:05 AM EDT - 2 months ago

REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026

Regenxbio price target raised to $32 from $27 at Baird

2026-06-23T10:44:38.000Z - 2 months ago

Regenxbio price target raised to $32 from $27 at Baird

H.C. Wainwright notes Regenxbio doesn’t need more studies for BLA resubmission

2026-06-22T13:58:16.000Z - 2 months ago

H.C. Wainwright notes Regenxbio doesn’t need more studies for BLA resubmission

Regenxbio aligns with FDA on path forward for Navsunli

2026-06-22T11:41:10.000Z - 2 months ago

Regenxbio aligns with FDA on path forward for Navsunli

REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II

Jun 22, 2026, 7:30 AM EDT - 2 months ago

REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II

FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports

Jun 22, 2026, 7:01 AM EDT - 2 months ago

FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports

FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says

Jun 22, 2026, 6:30 AM EDT - 2 months ago

FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says

REGENXBIO Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 20, 2026, 9:30 AM EDT - 3 months ago

REGENXBIO Transcript: RBC Capital Markets Global Healthcare Conference 2026

REGENXBIO to Participate in Upcoming Investor Conferences

May 18, 2026, 4:05 PM EDT - 3 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Earnings release: Q1 2026

May 14, 2026, 9:30 AM EDT - 3 months ago

REGENXBIO Earnings release: Q1 2026

REGENXBIO Quarterly report: Q1 2026

May 14, 2026, 9:30 AM EDT - 3 months ago

REGENXBIO Quarterly report: Q1 2026

REGENXBIO Transcript: Study result

May 14, 2026, 8:00 AM EDT - 3 months ago

REGENXBIO Transcript: Study result

REGENXBIO Press release: Study result

May 14, 2026, 8:00 AM EDT - 3 months ago

REGENXBIO Press release: Study result

REGENXBIO Slides: Study result

May 14, 2026, 8:00 AM EDT - 3 months ago

REGENXBIO Slides: Study result

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

May 14, 2026, 7:10 AM EDT - 3 months ago

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

Regenxbio's muscle disorder therapy meets main goal in late-stage study

May 14, 2026, 7:04 AM EDT - 3 months ago

Regenxbio's muscle disorder therapy meets main goal in late-stage study

REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202

May 14, 2026, 7:00 AM EDT - 3 months ago

REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

May 7, 2026, 7:05 AM EDT - 3 months ago

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

May 6, 2026, 7:05 AM EDT - 3 months ago

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

REGENXBIO Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 4 months ago

REGENXBIO Proxy statement: Proxy filing

REGENXBIO Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 4 months ago

REGENXBIO Proxy statement: Proxy filing

REGENXBIO Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 5 months ago

REGENXBIO Proxy statement: Proxy filing

SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD

Mar 26, 2026, 9:00 AM EDT - 5 months ago

SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD

Regenxbio's Duchenne gene therapy shows improved muscle function in trial

Mar 11, 2026, 12:00 PM EDT - 5 months ago

Regenxbio's Duchenne gene therapy shows improved muscle function in trial

REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

Mar 11, 2026, 11:45 AM EDT - 5 months ago

REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

REGENXBIO Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 1:30 PM EDT - 5 months ago

REGENXBIO Transcript: Barclays 28th Annual Global Healthcare Conference

REGENXBIO Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 9:20 AM EDT - 6 months ago

REGENXBIO Transcript: Leerink Global Healthcare Conference 2026

FDA reversals leave investors worrying about the fates of other experimental drugs

Mar 6, 2026, 11:33 AM EST - 6 months ago

FDA reversals leave investors worrying about the fates of other experimental drugs

DNLI MRNA WVE

RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST

Mar 5, 2026, 2:25 PM EST - 6 months ago

RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST

REGENXBIO Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:00 AM EST - 6 months ago

REGENXBIO Earnings Call Transcript: Q4 2025

REGENXBIO Annual report: Q4 2025

Mar 5, 2026, 8:00 AM EST - 6 months ago

REGENXBIO Annual report: Q4 2025

REGENXBIO Earnings release: Q4 2025

Mar 5, 2026, 8:00 AM EST - 6 months ago

REGENXBIO Earnings release: Q4 2025

REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Mar 5, 2026, 7:05 AM EST - 6 months ago

REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 4, 2026, 7:05 AM EST - 6 months ago

REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses

Mar 2, 2026, 5:58 PM EST - 6 months ago

REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Feb 25, 2026, 7:05 AM EST - 6 months ago

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

US FDA declines to approve Regenxbio's rare disease drug

Feb 9, 2026, 4:13 PM EST - 7 months ago

US FDA declines to approve Regenxbio's rare disease drug

REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

Feb 9, 2026, 4:05 PM EST - 7 months ago

REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action

Jan 29, 2026, 6:06 PM EST - 7 months ago

Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action

US FDA places clinical hold on Regenxbio's gene therapy trials

Jan 28, 2026, 7:46 AM EST - 7 months ago

US FDA places clinical hold on Regenxbio's gene therapy trials

REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs

Jan 28, 2026, 7:30 AM EST - 7 months ago

REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs

REGENXBIO Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 1:30 PM EST - 7 months ago

REGENXBIO Transcript: 44th Annual J.P. Morgan Healthcare Conference

REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program

Jan 11, 2026, 3:00 PM EST - 8 months ago

REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program

IGOTACALL
IGOTACALL Aug. 24 at 7:50 PM
$RGNX dippy yippy
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 24 at 7:18 PM
RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ‘Disappointing’ FDA Hold On Gene Therapy $RGNX $XBI $VTI https://stocktwits.com/news/equity/markets/rgnx-stock-on-track-for-worst-day-in-over-three-months-bof-a-says-buy-despite-disappointing-fda-hold-on-gene-therapy/cZYKq3aRJFj
0 · Reply
IGOTACALL
IGOTACALL Aug. 24 at 6:47 PM
$RGNX tomorrow 6 ready for the dip before the bell
0 · Reply
maphere
maphere Aug. 24 at 6:39 PM
$RGNX Could see a late breaking abstract end of Sept. at the WMS conference. Abstract submissions are due by this week and Regenxbio has more data on 202 to share. https://www.wms2026.com/page/late-breaking-abstracts
1 · Reply
rando321456
rando321456 Aug. 24 at 6:09 PM
$RGNX Silver lining to this is that there's probably been nothing too bad around the confirmatory trial for 202 as the FDA definitely would have slapped a hold on it if there was anything. *knocks on wood* It'll be interesting to see if there's any buying into any of their stuff now, there's a decent chance they get blackballed until any approvals actually happen.
2 · Reply
hhsll
hhsll Aug. 24 at 6:06 PM
$RGNX back over $10 within a week
0 · Reply
BioRich
BioRich Aug. 24 at 5:51 PM
$RGNX $CAPR $MLTX did you get your cheapies?
0 · Reply
severeblast
severeblast Aug. 24 at 5:35 PM
$RGNX Losers trend..
0 · Reply
Ml55totoag
Ml55totoag Aug. 24 at 5:34 PM
$RGNX
0 · Reply
InfoLib
InfoLib Aug. 24 at 5:34 PM
$RGNX FDA clinical hold changes the setup immediately. This is now a regulatory path and safety interpretation trade. The next useful information is scope of the hold, remediation path and whether timelines elsewhere in the program move with it.
1 · Reply
IGOTACALL
IGOTACALL Aug. 24 at 5:22 PM
$RGNX playing the 10/20 dip for tomorrow
1 · Reply
ApproxModDur
ApproxModDur Aug. 24 at 5:13 PM
$RGNX What implications would a US collapse have: https://youtu.be/mLPzQYq7lko
0 · Reply
nbkihy8
nbkihy8 Aug. 24 at 5:13 PM
$RGNX Playing the 5-7% bounce for tomorrow
0 · Reply
IGOTACALL
IGOTACALL Aug. 24 at 5:09 PM
$RGNX Dead cat bounce …
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 24 at 5:07 PM
$RGNX $OTLK Who might have a higher market cap than the other by September 1, 2027? $ABBV $JNJ
0 · Reply
kiwitc2000
kiwitc2000 Aug. 24 at 5:06 PM
$RGNX Clawing its way back from LOD.
0 · Reply
crpttic
crpttic Aug. 24 at 4:56 PM
$RGNX straight bloodbath since 2018
0 · Reply
BRITLS
BRITLS Aug. 24 at 4:50 PM
$RGNX volume seems pretty low for this type of event
0 · Reply
TickrTalk0007
TickrTalk0007 Aug. 24 at 4:38 PM
$RGNX second instance where safety is an issue... its clear the AAV is causing cancer albeit benign
0 · Reply
bigwave7759
bigwave7759 Aug. 24 at 4:37 PM
$RGNX Total BS on this MRI results. No ill effects on any of the patients. Please someone explaIn the hold by FDA?????
1 · Reply
notreload_ai
notreload_ai Aug. 24 at 4:34 PM
BofA calls the clinical hold on $RGNX RGX-121 (from silent spine MRI issues in 5 patients) disappointing, undoing July progress. No near-term resubmission expected; they already valued it little. Next catalyst: starting the ’202 BLA filing this quarter. Still Buy rated with $15 target.
0 · Reply
dcrown
dcrown Aug. 24 at 4:25 PM
$RGNX https://www.streetinsider.com/Analyst+Comments/Barclays+Downgrades+Regenxbio+Inc.+%28RGNX%29+to+Equalweight/26886397.html
0 · Reply